Abstract
The ryanodine receptor calcium release channel is central to cytoplasmic Ca 2+ signalling in skeletal muscle, the heart, and many other tissues, including the central nervous system, lymphocytes, stomach, kidney, adrenal glands, ovaries, testes, thymus, and lungs. The ion channel protein is massive (more than 2.2 MDa) and has a structure that has defied detailed determination until recent developments in cryo-electron microscopy revealed much of its structure at near-atomic resolution. The availability of this high-resolution structure has provided the most significant advances in understanding the function of the ion channel in the past 30 years. We can now visualise the molecular environment of individual amino acid residues that form binding sites for essential modulators of ion channel function and determine its role in Ca 2+ signalling. Importantly, the structure has revealed the structural environment of the many deletions and point mutations that disrupt Ca 2+ signalling in skeletal and cardiac myopathies and neuropathies. The implications are of vital importance to our understanding of the molecular basis of the ion channel’s function and for the design of therapies to counteract the effects of ryanodine receptor-associated disorders.
Keywords: Ryanodine Receptor, Skeletal and Cardiac Muscle, High Resolution Cryo-EM
Introduction
Intracellular Ca 2+ signalling in many tissues depends on Ca 2+ ions cycling between the bulk of the cytoplasm and specialised intracellular Ca 2+ stores in endoplasmic reticulum (ER). Ca 2+ is released from the stores through two classes of ion channel: the inositol 1,4,5-trisphosphate receptor (IP3R) and the ryanodine receptor (RyR) 1. Muscle contraction is almost entirely dependent on a massive outflow of Ca 2+ from the modified ER—sarcoplasmic reticulum (SR)—through RyR channels; relaxation then follows the return of Ca 2+ to the store by SERCA (sarcoplasmic endoplasmic reticulum calcium ATPase) pumps 1. The RyR opens in response to an action potential during excitation-contraction (EC) coupling. The action potential travels along the fibre surface and throughout the muscle fibre along transverse tubule extensions of the surface membrane, which forms multiple junctions with the SR membrane 2. The gap between the membranes is filled almost entirely by the cytoplasmic bulk of the RyR, which is embedded in the SR membrane ( Figure 1). In skeletal muscle, the action potential is detected by a surface membrane voltage sensor in the α 1S subunit of the dihydropyridine receptor (DHPR, also known as Ca V1.1) 3, 4. The signal from the action potential is transmitted to the RyR through a series of protein–protein interactions that are not yet fully defined but likely include the β 1a subunit of the DHPR and the STAC3 protein 5, 6. A simpler EC coupling system exists in the heart, where an action potential induces Ca 2+ entry through the cardiac DHPR (Ca V1.2) and the entering Ca 2+ ions activate the cardiac RyR2 in a Ca 2+-activated Ca 2+ release process 1. The massive RyR ion channel protein is composed of four monomers of more than 500 KDa. Its efficient operation depends on a myriad of factors that interact with its many domains. Such factors include associated proteins such as calmodulin, the FK506 binding proteins, and CLIC2, all of which bind to its large cytoplasmic domain. Binding to its tiny luminal domain are triadin, junctin, and the Ca 2+ binding protein calsequestrin 5. Other essential factors regulating the ion channel open probability and gating behaviour include post-translational modifications such as phosphorylation, oxidation, nitrosylation, nitration, and glutathiolation 7, 8. Acquired changes in channel function and genetically transmitted modifications can severely disrupt the ion channel’s function and detrimentally alter Ca 2+ signalling to lead to skeletal and cardiac myopathies that can be debilitating and often fatal. Despite the essential function of this ion channel protein, the molecular nature of its gating mechanisms and how they are disrupted in myopathies have remained elusive. Such insight required near-atomic resolution structures of the protein, which are now available with a resolution of not more than 6.1 Å following recent advances in cryo-electron microscopy (cryo-EM) 9– 16. Thus far, the more structurally stable RyR1 protein has been determined at the highest resolution of about 3.8 Å 10, 13 ( Figure 1). The highest resolution is achieved for the most stable parts of the protein, particularly the C-terminal portion encompassing the transmembrane/pore domains. The pore itself has been determined with highest resolution 17. Consequently, the high-resolution cryo-EM structure of the RyR protein is only partially resolved.
The impact of high-resolution structures of the ryanodine receptor
The enormous impact of the higher-resolution structures on our understanding of RyR function has been elegantly presented in full reviews by Meissner 17, Samsó 18, Zalk and Marks 19, and Santulli et al. 20. In particular, Meissner 17 and Samsó 18 provide excellent summaries of the different terminology applied to the various structural domains of the RyR, which have evolved in different ways as increasingly higher-resolution structures have been reported over the last 20 years. The various domains of RyR1 are shown in Figure 1 and Figure 2 and are based on Yan et al. 10 and Zalk et al. 9, respectively, and illustrate very different terminologies used by different authors. Different terminologies and residue numbers are summarised in Table 1 of 17. There are 10 significant domains in each RyR subunit: (1) the N-terminal domain, which is a hot spot in RyR1 and RyR2 for disease-causing mutations; (2) the SPRY1 domain that is part of the binding site for FKPB12 and, with SPRY3, forms a major part of the “clamp” region (older nomenclature) that closely opposes the T-tubule membrane and may interact indirectly with the DHPR α 1S subunit in EC coupling; (3) the Ry 1 and 2 or P2 domains; (4) the SPRY2 and 3 domain; (5) the junctional solenoid (Jsol or Handle), which also contributes to the FKBP binding pocket (see legend to Figure 1); (6, 7) bridging solenoid (Bsol encompassing helical domains 1 and 2) and containing the protein kinase A (PKA) and Ca 2+/calmodulin (CaM)-dependent protein kinase II (CaMKII) phosphorylation sites; (8) the core solenoid (Csol or central domain), which contains two EF hand Ca 2+ binding motifs; (9) the transmembrane domain (TMD) containing the Ca 2+ pore with binding sites for ryanodine and the luminal domain of the RyR with triadin and junctin binding sites; and (10) the C terminal domain (CTD) that forms part of the Ca 2+, ATP, and caffeine activation site.
The Ca 2+, ATP, and caffeine binding sites have been identified by comparing differences between RyR1 with Ca 2+, but not ATP or caffeine, and RyR1 with ATP and caffeine bound, but without Ca 2+ 13. All three activators bind within a small region of the protein in which the CTD comes into close approximation with the Csol domain and TMD. Ca 2+ binds at the interface between the CTD and CSol. ATP binds at the junction between the CTD, the cytoplasmic extension of the S6 transmembrane helix, and the “thumb and forefinger” region adjacent to CSol. Caffeine binds between the CTD and cytoplasmic extension of the S6 helix. As predicted from many previous biochemical and physiological studies 21– 24, the ryanodine binding site is within the pore and adjacent to residue Q4933.
Of particular importance to muscle physiology are the substantial differences between the structures of the skeletal (RyR1) and cardiac (RyR2) isoforms, which explain many of the functional differences between the proteins and their role in Ca 2+ signalling in the two tissues 17, 18, 25. Also of major importance for basic muscle physiology/biophysics are the structural changes determining ion channel gating between the open and closed states. The recent high-resolution structures of RyRs locked into open or closed conformations, in combination with previous lower-resolution structural studies, allow refined models of the ion channel gating mechanisms to be developed 13, 14, 16, 18, 20. This has been no easy task, as the ion channel opening and closing require the coordination of more than 40 domains and the transmission of allosteric changes from both cytoplasmic domains and luminal domains to the channel gating mechanism. As stated by Samsó 18, “the RyR is the quintessential allosteric machine”. Detailed summaries of RyR1 and RyR2 domain structures are given in several recent publications 13, 14, 16, 18, 20, 25. In addition, defined locations of essential ATP, caffeine, and Ca 2+ binding sites in RyR1 are reported by des Georges et al. 13, and these observations provide a basis for predictions of the location of similar sites in the RyR2 protein 27. It became apparent that the channel can exist in a variety of conformations, not simply “open or closed”. Indeed, priming changes in the C-terminal activation module can occur without altering pore structure, and there may be a hierarchy of pore structure changes that depend on binding of Ca 2+, ATP, or caffeine that have not yet been determined but can produce incremental changes in channel open probability 13. It is worth noting that the structure of the open channel may continue to be further refined as optimal conditions, including the lipid content of preparative solutions, are developed for cryo-EM structural studies 16.
Mutations in RyRs can lead to severe genetic conditions, including malignant hyperthermia (MH) and central core disease (CCD) in skeletal muscle 28 and arrhythmia in cardiac muscle 29. Locating the mutated residues in the full-length channel structure has been difficult in the past but is now possible with the high-resolution cryo-EM RyR structures 20. Although such mutations can occur at almost any region in the protein, there are specific “hot spots”. MH occurs when RyR1 is activated by a volatile anaesthetic and leads to a rapid rise in core body temperature and organ failure unless treated 30. MH mutations generally occur in central (Bsol) and N-terminal clusters in regions that would impact on pore opening and lead to uncontrollable Ca 2+ release in the presence of anaesthetics 20. CCD is characterised histologically by cores of inactive tissue in the centre of muscle fibres that lead to progressive muscle weakness 28. RyR1 mutations causing CCD are clustered in the C-terminal Ca 2+ binding site at the interface between the CTD and CSol, where they can directly affect the activation mechanism 20. Mutations in the cardiac RyR2 that lead to arrhythmias are generally located in the pore, transmembrane, and central domain regions, which are directly involved in channel activation and gating 13– 20.
Importantly, the detailed three-dimensional (3D) locations of disease-causing mutations in RyR1 and RyR2 and determination of structural changes associated with mutations that lead to disrupted Ca 2+ signalling will help in understanding the molecular process involved in regulating the ion channel gating mechanisms. In addition, the structure of potential drug binding sites opens the possibility of rational design of therapeutics to correct defective RyR channel function and restore healthy Ca 2+ signalling 20, 25, 31, 32. As an aside, the high-resolution structural studies have provided evidence supporting early insightful hypotheses that the functional consequences of some of the disease-causing mutations are caused by “unzipping” of essential inter-domain interactions and thereby favour the open unstable conformation of the channel 33– 35.
It is worth noting that X-ray crystallography has been used to predict the structure of individual elements within the RyR. X-ray crystal structures of isolated RyR domains at resolutions of less than 2 Å have been obtained and have defined the structures of ligand binding sites and also revealed structural changes induced by ligand binding or caused by mutations 33. X-ray crystal structures have been docked into the 3D envelope of RyR calculated from cryo-EM data to help interpret the high-resolution structures reported for RyR1 9– 11. This is further discussed in 17, 19, 36. The potential power of combining atomic resolution X-ray crystallography and nuclear magnetic resonance with cryo-EM to obtain high-resolution structures of large proteins of more than 500 KDa is discussed in detail in a review by Vénien-Bryan et al. 36.
The recent high-resolution cryo-EM structures have been pivotal in revealing the truly minute nature of the luminal domain of the RyR protein. Residues that comprise the “luminal” domain can be defined as those that extend from the SR membrane into the luminal compartment ( Figure 1 and Figure 2). The parts of the protein extending beyond the membrane likely consist only of short luminal loops linking the transmembrane helices 5 and 6 and the pore helix and thus constitute less than 1.5% of the protein mass 5. However, as the hydrophilic luminal environment extends into the highly charged domains of the channel pore, the actual amount of the protein exposed to the luminal solution is greater than the luminal loops that extend beyond the generalised membrane boundary. Nevertheless, it is remarkable that the luminal domain is relatively very small given the importance of luminal conditions in determining the open probability of RyR1 and RyR2 channel in vivo and in vitro. The open probability of the RyR channel is very sensitive to changes in luminal [Ca 2+], and changes in the RyR’s sensitivity to luminal Ca 2+ underlie the defects in Ca 2+ signalling that produce skeletal and cardiac myopathies 37, 38. In addition, the luminal domains provide the RyR binding sites for the associated regulatory proteins triadin and junctin ( Figure 3) 39, 40. These proteins anchor the RyR to the luminal Ca 2+ binding protein calsequestrin, and all three proteins impact on RyR1 and RyR2 activity. Mutations in any of the three luminal proteins can alter the functional interactions between the proteins and the luminal domain of the RyR. Such altered interactions lead to significant changes in RyR function and Ca 2+ signalling and produce significant cardiac and skeletal myopathies 5.
Concluding comments
The high-resolution cryo-EM revolution over the past four years has had a major impact on the interpretation of RyR physiology in terms of the specific structural changes within the RyR protein. The structure of the protein in the open and closed state reveals conformational changes in the pore that allow Ca 2+ flow from the SR and significant associated changes in the structure of remote cytoplasmic domains of the protein. The nature of structural re-organisation resulting from post-translational modifications and mutations can now be predicted and the predictions tested and refined in future cryo-EM studies of RyRs subjected to specific modifications or mutations. It is likely that some of the current structures, particularly those of the open conformations, will be further refined as yet higher-resolution structures become available and improved isolation conditions are developed.
It is also likely that the next major structural development will be the determination of the structure of the RyR in the intact adult mammalian muscle fibre, ideally in the environment of the junctional gap that separates the surface (T-tubule) membrane and the SR. This will reveal the RyR1 structure when it is associated with other proteins that are essential for EC coupling such as the DHPR α and β subunits, STAC3, and junctophilin. For those in the field, it is a continual frustration that we know these proteins are essential for EC coupling and we can construct models for their interactions but that we will never fully understand skeletal EC coupling until we have determined their 3D associations within the intact cell. This next step awaits the development of high-resolution tomography techniques, possibly cryo-EM tomography 18. Indeed, high-resolution tomography may also reveal the way in which RyR channels associate with each other in the SR membrane to allow “coupled gating” between neighbours, a phenomenon that is seen in lipid bilayers 41– 44 and that is thought to be critical to RyR function in muscle fibres 20, 45.
Editorial Note on the Review Process
F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).
The referees who approved this article are:
Andrew R Marks, Department of Physiology and Cellular Biophysics, Clyde and Helen Wu Center for Molecular Cardiology, New York, NY, USA; Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA
Montserrat Samso, Department of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, 23298, USA
Gerhard Meissner, Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, USA
Filip Van Petegem, Department of Biochemistry and Molecular Biology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, V6T 1Z3, Canada
Funding Statement
The author(s) declared that no grants were involved in supporting this work.
[version 1; referees: 4 approved]
References
- 1. Bers DM: Excitation-Contraction Coupling and Cardiac Contractile Force.2nd Edition ed. Developments in Cardiovascular Medicine.Dordrecht, The Netherlands: Kluwer Academic Publishers.2013. 10.1007/978-94-010-0658-3 [DOI] [Google Scholar]
- 2. Franzini-Armstrong C: Studies of the triad. 3. Structure of the junction in fast twitch fibers. Tissue Cell. 1972;4(3):469–78. 10.1016/S0040-8166(72)80023-5 [DOI] [PubMed] [Google Scholar]
- 3. Dulhunty AF: Excitation-contraction coupling from the 1950s into the new millennium. Clin Exp Pharmacol Physiol. 2006;33(9):763–72. 10.1111/j.1440-1681.2006.04441.x [DOI] [PubMed] [Google Scholar]
- 4. Dulhunty AF, Casarotto MG, Beard NA: The ryanodine receptor: a pivotal Ca 2+ regulatory protein and potential therapeutic drug target. Curr Drug Targets. 2011;12(5):709–23. 10.2174/138945011795378595 [DOI] [PubMed] [Google Scholar]
- 5. Dulhunty AF, Board PG, Beard NA, et al. : Physiology and Pharmacology of Ryanodine Receptor Calcium Release Channels. Adv Pharmacol. 2017;79:287–324. 10.1016/bs.apha.2016.12.001 [DOI] [PubMed] [Google Scholar]
- 6. Polster A, Nelson BR, Papadopoulos S, et al. : Stac proteins associate with the critical domain for excitation-contraction coupling in the II-III loop of Ca V1.1. J Gen Physiol. 2018;150(4):613–624. 10.1085/jgp.201711917 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 7. Zalk R, Lehnart SE, Marks AR: Modulation of the ryanodine receptor and intracellular calcium. Annu Rev Biochem. 2007;76:367–85. 10.1146/annurev.biochem.76.053105.094237 [DOI] [PubMed] [Google Scholar]
- 8. Denniss A, Dulhunty AF, Beard NA: Ryanodine receptor Ca 2+ release channel post-translational modification: Central player in cardiac and skeletal muscle disease. Int J Biochem Cell Biol. 2018;101:49–53. 10.1016/j.biocel.2018.05.004 [DOI] [PubMed] [Google Scholar]
- 9. Zalk R, Clarke OB, des Georges A, et al. : Structure of a mammalian ryanodine receptor. Nature. 2015;517(7532):44–9. 10.1038/nature13950 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 10. Yan Z, Bai X, Yan C, et al. : Structure of the rabbit ryanodine receptor RyR1 at near-atomic resolution. Nature. 2015;517(7532):50–55. 10.1038/nature14063 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 11. Efremov RG, Leitner A, Aebersold R, et al. : Architecture and conformational switch mechanism of the ryanodine receptor. Nature. 2015;517(7532):39–43. 10.1038/nature13916 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
- 12. Bai XC, Yan Z, Wu J, et al. : The Central domain of RyR1 is the transducer for long-range allosteric gating of channel opening. Cell Res. 2016;26(9):995–1006. 10.1038/cr.2016.89 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 13. des Georges A, Clarke OB, Zalk R, et al. : Structural Basis for Gating and Activation of RyR1. Cell. 2016;167(1):145–157.e17. 10.1016/j.cell.2016.08.075 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 14. Peng W, Shen H, Wu J, et al. : Structural basis for the gating mechanism of the type 2 ryanodine receptor RyR2. Science. 2016;354(6310): pii: aah5324. 10.1126/science.aah5324 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
- 15. Wei R, Wang X, Zhang Y, et al. : Structural insights into Ca 2+-activated long-range allosteric channel gating of RyR1. Cell Res. 2016;26(9):977–94. 10.1038/cr.2016.99 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 16. Willegems K, Efremov RG: Influence of Lipid Mimetics on Gating of Ryanodine Receptor. Structure. 2018;26(10):1303–1313.e4. 10.1016/j.str.2018.06.010 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
- 17. Meissner G: The structural basis of ryanodine receptor ion channel function. J Gen Physiol. 2017;149(12):1065–1089. 10.1085/jgp.201711878 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 18. Samsó M: A guide to the 3D structure of the ryanodine receptor type 1 by cryoEM. Protein Sci. 2017;26(1):52–68. 10.1002/pro.3052 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 19. Zalk R, Marks AR: Ca 2+ Release Channels Join the 'Resolution Revolution'. Trends Biochem Sci. 2017;42(7):543–555. 10.1016/j.tibs.2017.04.005 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 20. Santulli G, Lewis D, des Georges A, et al. : Ryanodine Receptor Structure and Function in Health and Disease. Subcell Biochem. 2018;87:329–352. 10.1007/978-981-10-7757-9_11 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 21. Witcher DR, McPherson PS, Kahl SD, et al. : Photoaffinity labeling of the ryanodine receptor/Ca 2+ release channel with an azido derivative of ryanodine. J Biol Chem. 1994;269(18):13076–9. [PubMed] [Google Scholar]
- 22. Callaway C, Seryshev A, Wang JP, et al. : Localization of the high and low affinity [3H]ryanodine binding sites on the skeletal muscle Ca 2+ release channel. J Biol Chem. 1994;269(22):15876–84. [PubMed] [Google Scholar]
- 23. Tanna B, Welch W, Ruest L, et al. : The interaction of an impermeant cation with the sheep cardiac RyR channel alters ryanoid association. Mol Pharmacol. 2006;69(6):1990–7. 10.1124/mol.105.021659 [DOI] [PubMed] [Google Scholar]
- 24. Ranatunga KM, Chen SR, Ruest L, et al. : Quantification of the effects of a ryanodine receptor channel mutation on interaction with a ryanoid. Mol Membr Biol. 2007;24(3):185–93. 10.1080/09687860601076522 [DOI] [PubMed] [Google Scholar]
- 25. Dhindwal S, Lobo J, Cabra V, et al. : A cryo-EM-based model of phosphorylation- and FKBP12.6-mediated allosterism of the cardiac ryanodine receptor. Sci Signal. 2017;10(480): pii: eaai8842. 10.1126/scisignal.aai8842 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
- 26. Yuchi Z, Yuen SM, Lau K, et al. : Crystal structures of ryanodine receptor SPRY1 and tandem-repeat domains reveal a critical FKBP12 binding determinant. Nat Commun. 2015;6:7947. 10.1038/ncomms8947 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Jones PP, Guo W, Chen SRW: Control of cardiac ryanodine receptor by sarcoplasmic reticulum luminal Ca 2. J Gen Physiol. 2017;149(9):867–875. 10.1085/jgp.201711805 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 28. Quane KA, Healy JM, Keating KE, et al. : Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet. 1993;5(1):51–5. 10.1038/ng0993-51 [DOI] [PubMed] [Google Scholar]
- 29. Lehnart SE, Mongillo M, Bellinger A, et al. : Leaky Ca 2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest. 2008;118(6):2230–45. 10.1172/JCI35346 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Rosenberg H, Davis M, James D, et al. : Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21. 10.1186/1750-1172-2-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Yuchi Z, Lau K, Van Petegem F: Disease mutations in the ryanodine receptor central region: crystal structures of a phosphorylation hot spot domain. Structure. 2012;20(7):1201–11. 10.1016/j.str.2012.04.015 [DOI] [PubMed] [Google Scholar]
- 32. Todd JJ, Sagar V, Lawal TA, et al. : Correlation of phenotype with genotype and protein structure in RYR1-related disorders. J Neurol. 2018;265(11):2506–2524. 10.1007/s00415-018-9033-2 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 33. Yamamoto T, El-Hayek R, Ikemoto N: Postulated role of interdomain interaction within the ryanodine receptor in Ca 2+ channel regulation. J Biol Chem. 2000;275(16):11618–25. 10.1074/jbc.275.16.11618 [DOI] [PubMed] [Google Scholar]
- 34. Bannister ML, Hamada T, Murayama T, et al. : Malignant hyperthermia mutation sites in the Leu 2442-Pro 2477 (DP4) region of RyR1 (ryanodine receptor 1) are clustered in a structurally and functionally definable area. Biochem J. 2007;401(1):333–9. 10.1042/BJ20060902 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Suetomi T, Yano M, Uchinoumi H, et al. : Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca 2+ release leading to catecholaminergic polymorphic ventricular tachycardia. Circulation. 2011;124(6):682–94. 10.1161/CIRCULATIONAHA.111.023259 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Venien-Bryan C, Li Z, Vuillard L, et al. : Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery. Acta Crystallogr F Struct Biol Commun. 2017;73(Pt 4):174–183. 10.1107/S2053230X17003740 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 37. Chen W, Koop A, Liu Y, et al. : Reduced threshold for store overload-induced Ca 2+ release is a common defect of RyR1 mutations associated with malignant hyperthermia and central core disease. Biochem J. 2017;474(16):2749–2761. 10.1042/BCJ20170282 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
- 38. Jiang D, Xiao B, Yang D, et al. : RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca 2+ release (SOICR). Proc Natl Acad Sci U S A. 2004;101(35):13062–7. 10.1073/pnas.0402388101 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Goonasekera SA, Beard NA, Groom L, et al. : Triadin binding to the C-terminal luminal loop of the ryanodine receptor is important for skeletal muscle excitation contraction coupling. J Gen Physiol. 2007;130(4):365–78. 10.1085/jgp.200709790 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Wium E, Dulhunty AF, Beard NA: Three residues in the luminal domain of triadin impact on Trisk 95 activation of skeletal muscle ryanodine receptors. Pflugers Arch. 2016;468(11–12):1985–1994. 10.1007/s00424-016-1869-7 [DOI] [PubMed] [Google Scholar]
- 41. Marx SO, Ondrias K, Marks AR: Coupled gating between individual skeletal muscle Ca 2+ release channels (ryanodine receptors). Science. 1998;281(5378):818–21. 10.1126/science.281.5378.818 [DOI] [PubMed] [Google Scholar]
- 42. Laver DR, O'Neill ER, Lamb GD: Luminal Ca 2+-regulated Mg 2+ inhibition of skeletal RyRs reconstituted as isolated channels or coupled clusters. J Gen Physiol. 2004;124(6):741–58. 10.1085/jgp.200409092 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Dulhunty AF, Pouliquin P, Coggan M, et al. : A recently identified member of the glutathione transferase structural family modifies cardiac RyR2 substate activity, coupled gating and activation by Ca 2+ and ATP. Biochem J. 2005;390(Pt 1):333–43. 10.1042/BJ20042113 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Gaburjakova J, Gaburjakova ML: Effect of luminal Ca 2+ on the stability of coupled gating between ryanodine receptors from the rat heart. Acta Physiol (Oxf). 2008;193(3):219–27. 10.1111/j.1748-1716.2008.01837.x [DOI] [PubMed] [Google Scholar]
- 45. Sobie EA, Guatimosim S, Gómez-Viquez L, et al. : The Ca 2+ leak paradox and rogue ryanodine receptors: SR Ca 2+ efflux theory and practice. Prog Biophys Mol Biol. 2006;90(1–3):172–85. 10.1016/j.pbiomolbio.2005.06.010 [DOI] [PMC free article] [PubMed] [Google Scholar]